Table 1 Various platforms of COVID-19 vaccines, types of vaccines, manufacturers and the phases it approached
Vaccine Platforms | Type of vaccines | Developers | Phases |
|---|---|---|---|
Inactivated viruses | VLA2001 | Valneva, National Institute for Health Research, United Kingdom | III |
TURKOVAC, | Erciyes University and the Health Institute Of Turkey (TUSEV) | III | |
CovIral-Varkat | Shifa Pharmed Industrial Co | II/III | |
Vero cell, BBIBP-CorV | Sinopharm | IV | |
Inactivated (NDV-based) chimeric vaccine with or without the adjuvant CpG 1018 | The Government Pharmaceutical Organization (GPO); PATH; Dynavax | I/II | |
Inactivated COVID-19 vaccine | KM Biologics Co., Ltd | II/III | |
Live attenuated virus | COVI-VAC | Codagenix/Serum Institute of India | III |
MV-014-212 | Meissa Vaccines, Inc | I | |
DNA based vaccines | COVIGEN | University of Sydney, Bionet Co., Ltd Technovalia | I |
COVID-eVax | Takis + Rottapharm Biotech | I/II | |
INO4800 + electropor-ation | Inovio Pharmaceuticals + International Vaccine Institute + Advaccine | III | |
AG0301-COVID19 | AnGes + Takara Bio + Osaka University | II/III | |
CORVax-12 | OncoSec Immunotherapies; Providence Health & Services | I | |
GX-19N | Genexine Consortium | II/III | |
GLS-5310 | Gene One Life Science, Inc | I/II | |
Protein subunit | VAT00008 | Sanofi Pasteur + GSK | III |
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) | Livzon Pharmaceutical | III | |
Recombinant SARS-CoV-2 vaccine (CHO Cell) | Institute of Microbiology, Chinese Academy of Sciences, AnhuiZhifeiLongcom Biopharmaceutical | III | |
CIGB-66 (RBD + aluminium hydroxide) | Center for Genetic Engineering and Biotechnology (CIGB) | III | |
RecombinantSars-CoV-2 Spike protein, Aluminumadjuvanted (Nanocovax) | Nanogen Pharmaceutical Biotechnology | III | |
EpiVac Corona | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | III | |
RNA based vaccines | mRNA-1273, mRNA-1273.351 | Moderna + National Institute of Allergy and Infectious Diseases (NIAID) | IV |
BNT162b2 (3 LNP-mRNAs), also known as "Comirnaty" | Pfizer/BioNTech + Fosun Pharma | IV | |
CVnCoV Vaccine | CureVac AG | III | |
ARCT-021 | Arcturus Therapeutics | II | |
LNP-nCoVsaRNA | Imperial College London | I | |
Chula Cov19 mRNA vaccine | Chulalongkorn University | I | |
SARS-CoV-2 mRNA vaccine (ARCoV) | Academy of Military Science (AMS), Walvax Biotechnology and Suzhou Abogen Biosciences | III | |
Viral vector (non-replicating) | Recombinant novel coronavirus vaccine(Adenovirus type 5 vector) | CanSino Biological Inc./Beijing Institute of Biotechnology | IV |
Sputnik V (Gam-COVID-Vac) Adeno-based (rAd26-S + rAd5-S) | Gamaleya Research Institute; Health Ministry of the Russian Federation | III | |
Ad26.COV2.S | Janssen Pharmaceutical | IV | |
GRAd-COV2 (Replication defective Simian Adenovirus (GRAd encoding S) | ReiThera + Leukocare + Univercells | II/III | |
VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform | Vaxart | II | |
MVA-SARS-2-S | University of Munich (Ludwig-Maximilians) | I | |
Viral Vectors (Replicating) | DelNS1-2019-nCoV-RBD-OPT1 (Intranasalflu- based-RBD) | University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy | III |
rVSV-SARS-CoV-2-S Vaccine | Israel Institute for Biological Research | II/III | |
Virus like particle | Corona virus- Like Particle COVID-19 (CoVLP) | Medicago Inc | III |
RBD SARS-CoV-2 HBsAg VLP vaccine | Serum Institute of India + Accelagen Pty + SpyBiotech | I/II | |
VBI-2902a | VBI Vaccines Inc | I/II | |
SARS-CoV-2 VLP Vaccine | The Scientific and Technological Research Council of Turkey | II | |
ABNCoV2 capsid virus-like particle (cVLP) ± adjuvant MF59 | Radboud University | I |